Sign in
CompletedNo phase

Early Stop(Ruling) of the Antibiotic Treatment During Pneumopathies d' Inhalation

Key facts

Who runs it
University Hospital, Lille
Where
France2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
266 people enrolled
Started
20 Sept 2019
Ended
22 Feb 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • PCR-based microbiological diagnosis strategy
  • Standard microbiological diagnosis strategy
Record updated
23 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • presence of risk factors for aspiration :
  • known or likely swallowing dysfunction,
  • altered consciousness,
  • cardiac arrest,
  • difficult intubation
  • witnessed aspiration
  • symptoms and signs suggestive of lower respiratory tract pathology
  • temperature ≥38.5°C or <36°C
  • leukocyte count ≥10 000/µL or <1500/µL
  • purulent sputum or tracheal aspirate
  • new radiographic infiltrate on chest X-ray
  • tracheal intubation and mechanical ventilation since less than 48 hours

Who cannot take part

  • severe immunosuppression: leukocytes<1000/L or neutrophils<500/L, chemotherapy during the last 3 months, organ transplant with chronic immunosuppressors use, HIV (CD4<50), and chronic corticosteroid use (>0.5 mg/kg day for at least one month during the last three months)
  • pregnant women
  • refuse to participate to the study
  • no informed consent
  • documented bacteremia
  • septic shock
  • moribund patients (SAPS II >90)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The two most common consequences resulting from aspiration are chemical pneumonitis and bacterial aspiration pneumonia. Both entities present with comparable clinical signs and symptoms. In the absence of a reliable clinical or biological marker to differentiate between these two conditions, most patients with suspected aspiration are treated empirically with antibiotics. De-escalation of initial antibiotic treatment is encouraged based on the results of microbiological results, usually performed before starting antimicrobial treatment. However, in most hospitals, 48-72h are required to obtain the results of microbiological cultures, and to de-escalate empirical large spectrum antibiotic treatment.

Read full original descriptionShow less

The use of the Unyvero®, a multiplex PCR-based testing system, for detection of respiratory bacterial pathogens would allow decreasing the percentage of patients with aspiration syndrome who will receive unappropriated antibiotic treatment at Day 3.

The 2 groups in the trial

  • multiplex PCR strategyTreatment being tested

    FilmArray® Pneumonia Panel plus

    Treatment: PCR-based microbiological diagnosis strategy

  • standard strategyExisting treatment, for comparison

    Treatment: Standard microbiological diagnosis strategy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of a Strategy Based on the Unyvero® Testing System on Appropriate Antimicrobial Treatment in Patients With Suspected Aspiration Pneumonia Requiring Mechanical Ventilation : a Randomized Controlled Unblinded Trial
Record updated
23 December 2025